ADVFN Logo ADVFN

Hot Features

Registration Strip Icon for monitor ブラジル証券取引所、NASDAQ、NYSE、AMEX、LSEなどの主要取引所からの複数のリアルタイム株価を監視します。
AB Corporate Bond ETF

AB Corporate Bond ETF (EYEG)

35.23
-0.06
(-0.17%)
終了 1月30日 6:00AM
35.23
0.00
( 0.00% )
プレマーケット: 6:05PM

ポートフォリオを強化: リアルタイムのディスカッションと実用的な取引アイデア。

主要統計と詳細

通貨
35.23
買値
32.10
売値
56.01
出来高
-
0.00 日の範囲 0.00
34.52 52 週間の範囲 37.24
時価総額
前日終値
35.23
始値
-
時刻
最終取引時間
-
財務取引量
-
VWAP
-
平均取引量 (3 か月)
3,398
発行済株式数
7,689,000
配当利回り
-
PER
-2.33
1 株当たり利益 (EPS)
-1.7
歳入
-
純利益
-13.05M

AB Corporate Bond ETF について

The Fund is an actively-managed exchange-traded fund (ETF). The Fund pursues its objective by investing, under normal circumstances, at least 80% of its net assets, including any borrowings for investment purposes, in investment grade fixed-income securities of corporate issuers. Corporate issuers m... The Fund is an actively-managed exchange-traded fund (ETF). The Fund pursues its objective by investing, under normal circumstances, at least 80% of its net assets, including any borrowings for investment purposes, in investment grade fixed-income securities of corporate issuers. Corporate issuers may include corporate or other business entities in which a sovereign or governmental agency or entity may have, indirectly or directly, an interest, including a majority or greater ownership interest. The Funds investment objective is to maximize total return through current income and longterm capital appreciation. 詳細を表示

セクター
Pharmaceutical Preparations
業界
Pharmaceutical Preparations
ウェブサイト
本社
Wilmington, Delaware, USA
設立
-
AB Corporate Bond ETF is listed in the Pharmaceutical Preparations sector of the ナスダック市場 with ticker EYEG. The last closing price for AB Corporate Bond ETF was US$35.23. Over the last year, AB Corporate Bond ETF shares have traded in a share price range of US$ 34.52 to US$ 37.24.

AB Corporate Bond ETF currently has 7,689,000 shares in issue. The market capitalisation of AB Corporate Bond ETF is US$270.88 million. AB Corporate Bond ETF has a price to earnings ratio (PE ratio) of -2.33.

EYEG 最新ニュース

EyeGate Pharmaceuticals to Present at BIO CEO & Investor Conference in New York City

WALTHAM, Mass., Jan. 29, 2019 (GLOBE NEWSWIRE) -- EyeGate Pharmaceuticals, Inc. (NASDAQ: EYEG) (“EyeGate” or “the Company”) today announced that the Company will attend and present at the 21st...

EyeGate Pharmaceuticals Announces Meeting Date with FDA

WALTHAM, Mass., Jan. 16, 2019 (GLOBE NEWSWIRE) -- EyeGate Pharmaceuticals, Inc. (NASDAQ: EYEG) (“EyeGate” or “the Company”) today confirmed that it is scheduled to meet with the U.S. Food and...

EyeGate Pharmaceuticals Reports Third Quarter 2018 Financial Results and Provides Business Update

WALTHAM, Mass., Nov. 13, 2018 (GLOBE NEWSWIRE) -- EyeGate Pharmaceuticals, Inc. (NASDAQ: EYEG) (“EyeGate” or “the Company”) today announced financial results for the three-month period ended...

EyeGate Pharma Announces Positive Results in Second PRK Study

Data confirms results from earlier study WALTHAM, Mass., Nov. 13, 2018 (GLOBE NEWSWIRE) -- EyeGate Pharmaceuticals, Inc. (NASDAQ: EYEG) today announced top-line data from its study evaluating...

EyeGate Pharmaceuticals Signs Technology Transfer and License Agreement with SentrX Animal Care

WALTHAM, Mass., Oct. 02, 2018 (GLOBE NEWSWIRE) -- EyeGate Pharmaceuticals, Inc. (NASDAQ: EYEG) a clinical-stage, specialty pharmaceutical company with two proprietary platform technologies for...

EyeGate Pharmaceuticals Granted Additional 180 Days to Comply With Nasdaq Listing Rules

WALTHAM, Mass., Sept. 25, 2018 (GLOBE NEWSWIRE) -- EyeGate Pharmaceuticals, Inc. (NASDAQ: EYEG) a clinical-stage, specialty pharmaceutical company with two proprietary platform technologies for...

EyeGate Pharmaceuticals Completes Enrollment in Both PRK and PE Pilot Studies

WALTHAM, Mass., Sept. 24, 2018 (GLOBE NEWSWIRE) -- EyeGate Pharmaceuticals, Inc. (NASDAQ: EYEG) a clinical-stage, specialty pharmaceutical company with two proprietary platform technologies for...

EyeGate Announces Randomization of First Patients in Study for Punctate Epitheliopathies

WALTHAM, Mass., Sept. 04, 2018 (GLOBE NEWSWIRE) -- EyeGate Pharmaceuticals, Inc. (NASDAQ: EYEG) a clinical-stage, specialty pharmaceutical company with two proprietary platform technologies for...

EyeGate Announces Top-Line Results for Phase 3 Trial of EGP-437 in Anterior Uveitis

WALTHAM, Mass., Sept. 04, 2018 (GLOBE NEWSWIRE) -- EyeGate Pharmaceuticals, Inc. (NASDAQ: EYEG) a clinical-stage, specialty pharmaceutical company with two proprietary platform technologies for...

期間 †前日比前日比 %始値高値安値平均出来高VWAP
10.20.57093919497635.0335.29535.03353835.11412197SP
40.20.57093919497635.0335.29534.55589435.10469767SP
12-0.575-1.6059209607635.80536.4434.555339835.89248055SP
26-0.6654-1.8537194180935.895437.2434.555195136.0728287SP
52-0.5497-1.5363460286135.779737.2434.52120135.88988409SP
1560.030.085227272727335.237.2434.52110035.88863522SP
2600.030.085227272727335.237.2434.52110035.88863522SP

ムーバー

すべて表示
  • 出来高
  • 値上がり率
  • 値下がり率
銘柄コード株価出来高
ATHEAlterity Therapeutics Limited
US$ 6.07
(108.59%)
1.8M
NAOVNanoVibronix Inc
US$ 0.7317
(90.80%)
15.89M
CFSBCFSB Bancorp Inc
US$ 12.00
(57.27%)
6
GDEVGDEV Inc
US$ 24.99
(56.29%)
1
RBBRBB Bancorp
US$ 29.99
(54.03%)
7
CRGXCARGO Therapeutics Inc
US$ 3.42
(-74.07%)
410.16k
ECBKECB Bancorp Inc
US$ 8.01
(-41.49%)
5
FBLAFB Bancorp Inc
US$ 7.01
(-40.34%)
7
CEPOCantor Equity Partners I Inc
US$ 6.01
(-40.26%)
1
AURAAura Biosciences Inc
US$ 5.02
(-36.62%)
11
NAOVNanoVibronix Inc
US$ 0.7317
(90.80%)
15.89M
XFORX4 Pharmaceuticals Inc
US$ 0.872
(18.61%)
10.05M
MGOLMGO Global Inc
US$ 0.1282
(26.06%)
7.95M
TSLLDirexion Daily TSLA Bull 2X Trust ETF
US$ 25.65
(3.72%)
2.5M
ATHEAlterity Therapeutics Limited
US$ 6.07
(108.59%)
1.8M

最近閲覧した銘柄

Delayed Upgrade Clock